Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omeros Corp.

www.omeros.com

Latest From Omeros Corp.

Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Drug Review

Interview: The Pace Quickens For Calliditas's Berger's Disease Candidate

A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and boost the growth potential for the Swedish biotech.

 

 

Immune Disorders Strategy

Hazards Ahead For New Drugs At US FDA Amid Safety Concerns, Shutdown Disruption

The pipeline for new drug candidates remains healthy as 2019 begins, with almost 40 novel agents already under FDA review. But the chances of another record-breaking year are threatened by a confluence of safety issues that are putting risk management back in the spotlight – and by the widening ripple effects of the recent US government shutdown.

Drug Review Approvals

Tech Transfer Roundup: Roivant Taps Research Labs For New Gene Therapies

In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
    • Generic Drugs
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Inflammation
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Omeros Corp.
  • Senior Management
  • Gregory A Demopulos, MD, Chmn. & CEO
    Timothy M Duffy, PhD, VP, Bus. Dev.
    George A Gaitanaris, MD, PhD, CSO
    Eckard Leifke, MD, VP, Clin. Dev. & CMO
  • Contact Info
  • Omeros Corp.
    Phone: (206) 676-5000
    201 Elliott Ave. W.
    Seattle, WA 98119
    USA
UsernamePublicRestriction

Register